Dual bronchodilators have emerged as the primary treatment for chronic obstructive pulmonary disease (COPD). The latest report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD), version 2024, recommends the use of the combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) as an initial pharmacological treatment for symptomatic patients regardless of exacerbation risk, categorized by the new grades and severity system of COPD. The guidelines also place strong emphasis on patient-centered care, encouraging active involvement of patients in the selection of inhaler devices and providing education on proper inhaler techniques to improve treatment adherence and overall clinical outcomes.

In this informative video, Professor John Hurst delves into the crucial role of dual bronchodilators and the selection of appropriate inhaler devices in optimizing the management of COPD. He sheds light on the significance of peak inspiratory flow rate (PIFR) in the process of selecting the right inhaler device and recommends devices that are suitable for patients with low PIFR, as this can significantly enhance clinical outcomes.